Get the Stockscreener App
26.01
0.95%
-0.25
Pacira Biosciences Inc stock is traded at $26.01, with a volume of 115.19K.
It is down -0.95% in the last 24 hours and up +39.24% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See More
Previous Close:
$26.26
Open:
$26.41
24h Volume:
115.19K
Relative Volume:
0.15
Market Cap:
$1.21B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
17.94
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-1.22%
1M Performance:
+39.24%
6M Performance:
+16.48%
1Y Performance:
-8.70%
1-Day Range:
$26.00
$26.51
1-Week Range:
$25.06
$27.17
52-Week Range:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
813-553-6680
Address
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.05 | 1.21B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
171.90 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.55 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.535 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.75 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
122.09 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - PR Newswire
Pacira BioSciences Inc (PCRX) Shares Decline Despite Market Challenges - The News Heater
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - PR Newswire
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - GlobeNewswire
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire Inc.
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Is Pacira BioSciences Inc (PCRX) a good investment opportunity? - US Post News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Executive Shakeup at Pacira: New CCO and CBO Join with Multimillion-Dollar Equity Package - StockTitan
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their Rights in Connection with the Class Action - PR Newswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF - The Bakersfield Californian
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to - The Bakersfield Californian
Should You Buy Pacira (PCRX) After Golden Cross? - Zacks Investment Research
Pacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Lifted by Gagnon Securities LLC - MarketBeat
The Recovery Playbook: Non-Opioid Pain Management Options After Surgery - NOLA.com
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire
Upward Trajectory: Pacira BioSciences Inc (PCRX) Posts a Slidee, Closing at 25.75 - The Dwinnex
Views of Wall Street’s Leading Experts on Pacira BioSciences Inc - SETE News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire
IMPORTANT NOTICE: IF YOUR FINANCIAL ADVISOR RECOMMENDED PACIRA BIOSCIENCES INVESTMENTS PLEASE CONTACT KT LAW - EIN News
Pacira BioSciences Inc (PCRX) Becoming More Attractive for Investors - Knox Daily
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira LawsuitPCRX - PR Newswire
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by SG Americas Securities LLC - Defense World
Shareholders that lost money on Pacira BioSciences, Inc. - GlobeNewswire
Pacira BioSciences (NASDAQ:PCRX) Stock Rating Upgraded by Truist Financial - MarketBeat
Shareholders that lost money on Pacira BioSciences, Inc. (PCRX) should contact The Gross Law Firm about pending Class ActionPCRX - yourbigsky.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders - PR Newswire
ROSEN, A HIGHLY RECOGNIZED FIRM, Encourages Pacira - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure - The Bakersfield Californian
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Pacira upgraded at Truist citing end to eVenus patent dispute - MSN
Nisa Investment Advisors LLC Boosts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacer Advisors Inc. Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira - Longview News-Journal
Pacira BioSciences soars 62% following InvestingPro's October Fair Value alert - MSN
PCRX Stockholders Should Contact Shareholder Rights Firm - GlobeNewswire
Pacira BioSciences soars 62% following InvestingPro's October Fair Value alert By Investing.com - Investing.com Canada
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - Victoria Advocate
PCRX Stockholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Marketscreener.com
What 8 Analyst Ratings Have To Say About Pacira BioSciences - Benzinga
Pacira BioSciences stock upgraded at Truist (PCRX:NASDAQ) - Seeking Alpha
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira - GlobeNewswire
Pacira Announces Updates to Board of Directors - GlobeNewswire
Pacira Pharmaceuticals Implements New Board Leadership for Growth - TipRanks
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):